Compare Godaddy Inc (GDDY) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Medpace Holdings Inc — how do they compare? Godaddy Inc trades at $104.37 (market cap $13.07B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and Medpace Holdings Inc for 14 Days on average.
| GDDY | MEDP | |
|---|---|---|
Market Cap | $13.07B | $16.82B |
Volume | 1,831,274 | 223,093 |
Sector | Technology | Health |
52-Week High | $135.18 | $630.19 |
52-Week Low | $75.07 | $393.42 |
Typical Hold Time | 64 Days | 14 Days |
Enterprise Value | $15.75B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $103.19, up 6.15% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $4.95B revenue, 17.83% net margin, and consistent earnings beats in recent quarters. However, the stock faces headwinds from multiple securities class action lawsuits alleging misrepresentation of domain contract terms during September 2025-February 2026 period, creating significant legal overhang despite positive operational performance.
While GoDaddy maintains strong profitability and analyst support (58% buy ratings), the legal challenges present substantial near-term risk. The stock trades above consensus price target of $96.20, suggesting limited upside potential. Investors must weigh robust financial performance against litigation uncertainties that could impact shareholder value through settlements or reputational damage.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
